disease and before therapy was started. In this group, 28 patients had nodular sclerosis histology, and 3 had unclassified histologies. Five (16%) of 31 patients had elevated IL-13 levels; 3 had stage II disease, and 2 had stage III disease. Only one had B symptoms. The median serum IL-13 level was 46 pg/mL (range, 42 to 48 pg/mL).
To the editor:
Is hydroxyurea leukemogenic in children with sickle cell disease?
Hydroxyurea (HU) has been used for more than 10 years in children severely affected with sickle cell disease (SCD) to reduce the number of painful episodes. Short-to medium-term tolerance of the drug is good. [1] [2] [3] Concern remains, however, about the long-term safety of the drug and, in particular, its leukemogenic potential. Leukemia has been reported in myelodysplastic syndromes after at least 3 to 4 years of exposure to the drug, 4-5 so only long-term studies including significant numbers of patients can resolve concern for SCD. So far, 3 studies on long-term effects of HU in SCD children have been published (Table 1) . [6] [7] [8] Ferster et al 8 refer to a malignancy observed in one SCD patient on HU, the details of which were published in an abstract reporting the European experience with HU use in SCD children. 9 We believe it is important to emphasize that this leukemia occurred in a 10-year-old girl who had been treated with HU for only 7 weeks when acute lymphoblastic leukemia, with evidence of Philadelphia chromosome, was disclosed. 7 It is likely that her bone pains, which were the reason for initiating HU therapy, were the first manifestations of the malignancy. Furthermore, the type of leukemia was not typical of secondary malignancy. In our opinion, this leukemia was not related to HU treatment. Thus, so far, no leukemia has been related to HU treatment in SCD children. However, a case of leukemia with background cells suggesting myelodysplasia was reported in a 27-year-old SCD patient on HU treatment for 8 years. 10 Given that the number of children with long-term exposure to HU is still small, no conclusions about the long-term safety of HU in SCD can be drawn, and we think that the indications for treatment in children must remain cautious. To the editor:
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is caused by a t(9;22)(q34;q11) reciprocal translocation that generates a BCR-ABL fusion gene on the 22q-or Philadelphia (Ph) chromosome and an ABL-BCR gene on 9qϩ. 1, 2 Large deletions adjacent to the t(9;22) breakpoint on the derivative 9qϩ chromosome have now been found, which result in genomic loss at both sides of the translocation breakpoint. 3, 4, 5, 6 Recently, Huntly et al 7 analyzed a large series of CML patients and confirmed that these deletions identify a subgroup of patients with relatively poor prognosis. However, the molecular basis of this survival disadvantage has not been identified. Due to its unique location spanning the chromosome 9/chromosome 22 junction, ABL-BCR appears as the most likely candidate for this role for the following reasons: (1) it occupies the minimal region of deletion in the reported cases 6 ; (2) it is a "single-allele" gene whose deletion would result directly in total absence of the gene product, without a need to invoke a second event in a "2-hit" model 8 ; and (3) it is known not to be expressed in approximately one third of CML patients, 2,9 a frequency similar to that found for the 9qϩ deletions. 6 To investigate this hypothesis, we performed reverse transcription-polymerase chain reaction (RT-PCR) amplification of the BCR-ABL and ABL/BCR genes in a total of 519 patients (344 from the German CML studies III or IIIA 10 and 175 from the Hammersmith Hospital) diagnosed with BCR-ABL-positive CML between December 1981 and December 2000. The entire group comprised 319 males and 200 females with a median age of 50.6 years (range, 12.4-83.2). After diagnosis, patients were treated with either interferon-␣ and/or other chemotherapy (n ϭ 399), stem cell allograft (n ϭ 100), or autograft (n ϭ 20). RT-PCR amplifications were done as previously described. 11, 12 Approximately equal numbers expressed b2a2 or b3a2 transcripts, with a minority in whom both types of transcripts were present (Table 1) . ABL(1b)-BCR message was detected in 282/520 (54%) patients, encoding the classic 1bb3, 1bb4, or both 1bb3 and 1bb4 junctions in the great majority of cases. ABL(1a)-BCR transcripts were detected in only 8% of the patients. All frequencies are consistent with previous studies. 9 We analyzed a representative sample of 24 BCR-ABL-positive cases by fluorescence in situ hybridization (D-FISH) with commercially available BCR and ABL probes (Vysis, Richmond, UK), as described by Huntly et al. 7 Eleven of the 24 patients were ABL-BCR positive, exhibited a classical t(9;22) and, as expected, did not have a 9qϩ deletion. The remaining 13 patients did not express ABL-BCR and comprised 9 Ph-positive patients, 1 Phnegative patient, and 3 patients with complex translocations. Only 7 of the 13 (54%) ABL-BCR-negative cases had a deletion: in 3 of these, both chromosome 9-and 22-derived material was missing, 3 had only chromosome 9-derived material missing, and one lacked exclusively chromosome 22-derived material. These results show that the overall correlation between ABL-BCR expression and deletion at the 9qϩ derivative is relatively poor, with 6/24 (25%) cases being discordant.
We next assessed whether ABL-BCR expression could influence survival. A total of 471 patients with more than 30 days of follow-up after diagnosis were eligible for analysis. Probability of survival at 5 years was 51.8% (95% confidence interval [CI], 43-60) in the ABL-BCR-negative group (n ϭ 224) and 57.6% (95% CI, 49-66) in the positive group (n ϭ 247, P ϭ .49) (Figure 1 ). There were no differences between the ABL-BCR-positive and -negative patients with regard to gender, age, type of BCR-ABL transcript, treatment modality, and Sokal 13 or Hasford 14 score. Likewise, no significant difference in survival was observed between patients with b3a2 and b2a2 BCR-ABL transcripts or between ABL-BCR 1bb3 and 1bb4.
These results show that lack of ABL-BCR expression does not correlate with the presence of large deletions on the 9qϩ derivative or with a shorter survival in CML patients. Since the powerful negative prognostic value of the 9qϩ deletion has been confirmed For personal use only. on January 26, 2018. by guest www.bloodjournal.org From
